Latest Abbott Laboratories (ABT) Headlines Smar
Post# of 70
Posted On: 03/13/2014 7:52:26 PM
Latest Abbott Laboratories (ABT) Headlines
SmarTrend Watching for Potential Rebound in Shares of Abbott Laboratories After 1.08% Loss
Comtex SmarTrend(R) - 1 hr 27 mins ago
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $39.10 to a high of $39.82. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $39.41 on volume of 7.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Pre-Market Health Care Stocks Analysis: Medtronic, Abbott Laboratories, Hologic, and ArthroCare
PR Newswire - Thu Mar 13, 7:00AM CDT
On Wednesday, March 12, 2014, the NASDAQ Composite ended at 4,323.33, up 0.37%, the Dow Jones Industrial Average fell 0.07% to 16,340.08, and the S&P 500 closed at 1,868.20, up 0.03%. The gains were narrow based as four out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 687.90, down 0.01%, while the same has gained 3.36% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Hologic Inc. (NASDAQ: HOLX), and ArthroCare Corporation (NASDAQ: ARTC). Free research on these four companies can be accessed at:
2014 Hormone Replacement Therapy Global Strategic Business Report - IMS Consensus Guidelines Paving Way for More Clarity of HRT
M2 - Thu Mar 13, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/657h9p/hormone) has announced the addition of the "Hormone Replacement Therapy (HRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Hormone Replacement Therapy (HRT) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS & ISSUES 4. COMPETITIVE LANDSCAPE 5. THERAPY PROFILE - A REVIEW OF SELECT RECENT STUDIES CONDUCTED - Researchers at Yale University Discover Discontinuation HRT May Lead to Premature Deaths - Bioidenticals versus Synthetic Hormone Replacement Therapy Agents - Studies at University of Sydney Researchers Reveal the Safety of Short-Term Unopposed Estrogens - US Researchers Reveal HRT Risks May be Dependent on Weight and Other Factors - Studies Prove HRT to Lower Risk of Pancreatic Cancer - University of Texas Reveal HRT Linked to Risks of Kidney Stones - Researchers at the Sundsvall Hospital Demonstrate Increased Incidence of Cataract Development in Women Undergoing HRT - Researchers at University of Southern California Demonstrate Estrogen Replacement Therapies Lower Stress Levels in Older Women - Studies at Uppsala University Hospital Demonstrate HRT is Associated with Improved Muscle Functioning in Postmenopausal women - Finnish Study Reveals HRT Usage Assist in the Treatment of Hot Flashes in Post Menopausal Women - Researchers at Johns Hopkins University Demonstrate Women Undergoing Hormone Therapy Less Prone to Alzheimer's Disease - French Study Reveals Hormone Replacement Pills May Affect Gall Bladder - Danish Studies Proves HRT Lowers Risk of Heart Attack and Heart Failure 6. PRODUCT OVERVIEW 7. PRODUCT INTRODUCTIONS/APPROVALS - Pfizer Receives FDA Approval for DUAVEE for Treatment of Vasomotor Symptoms - Noven Pharmaceuticals Launches Brisdelle Capsules - Lawley Pharmaceuticals Launches Profeme progesterone Bioidentical Hormone Replacement Cream - Bayer Receives FDA Approval for Low-Dose ANGELIQ? Tablets - Noven Pharmaceuticals Receives USFDA Approval for Minivelle - Mylan Pharmaceuticals Introduces Letrozole Tablets - Novo Nordisk Unveils Vagifem? 10?g - Amgen Obtains FDA Approval for Prolia in Treating Postmenopausal Women at Greater Risk of Osteoporosis 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 40 companies including many key and niche players such as: - Abbott Laboratories - AbbVie - Actavis - Bayer Pharma - Bayer Pharma's Hormone Replacement Therapy Product Pipeline - Hisamitsu Pharmaceutical - Noven Pharmaceuticals - Merck Sharp & Dohme - Novartis - Novo Nordisk - Orion - Pfizer - Rottapharm Madaus - Teva Pharmaceutical Industries - TherapeuticsMD - Upsher-Smith Laboratories For more information visit http://www.researchandmarkets.com/research/657h9p/hormone About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Chinese Adalimumab Market Report - Forecasts to 2018
M2 - Wed Mar 12, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/936hbj/investigation) has announced the addition of the "Chinese Adalimumab Market Report - Forecasts to 2018" report to their offering. Adalimumab is a TNF (tumor necrosis factor) inhibiting anti-inflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA. Duo to large market size, challenging R&D and high profit of the monoclonal antibody drug market, the collaboration between Huahai Pharmaceutical and Oncobiologics is praised by the industry as the ""Second Transformation"" supported by the international biopharmaceutical giant's strong R&D strength. The approval for adalimumab to launch phase I clinical trial means a significant progress of the collaboration. However, follow-up R&D of the monoclonal antibody product requires a large amount of time before the product appears on the market. It is estimated that Abbott will continue to occupy the global market of adalimumab in the next few years. However, the situation will change gradually after 2017. Key Topics Covered: 1 Relevant Concepts of Adalimumab 2 Market Overview of Adalimumab in China, 2010-2013 3 Investigation on Sales Value of Adalimumab in China, 2010-2013 4 Investigation on Market Share of Major Adalimumab Manufacturers in China, 2010-2013 5 Investigation on Market Size of Adalimumab by Dosage Form in China, 2010-2013 6 Reference Price of Adalimumab in China Adalimumab Hospital Market, 2013 7 Analysis on Major Adalimumab Manufacturers in China, 2010-2013 8 Prospect of China Adalimumab Market, 2014-2018 Companies Mentioned - AbbVie - BASF Bioresearch Corporation - BASF Pharma - Huahai Pharmaceutical For more information visit http://www.researchandmarkets.com/research/93...estigation
Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Wed Mar 12, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mdgmns/rapid_medical) has announced the addition of the "Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid medical diagnostic kits market is experiencing impressive growth globally because of the continuous increase in demand for preventive management of infectious diseases. Since its introduction, rapid medical diagnostic kits are becoming a vital part of the medical diagnostics industry and the scope of this market has been perpetually increasing in terms of detectable diseases and adoption by end users. This report studies the global market for rapid diagnostic kits through three major perspectives namely, application areas, technologies and geography. The application segment of this market has been further segmented into three sub-divisions namely clinical testing, home-use and veterinary diagnostics. In addition, the technology segment of rapid medical diagnostic kits market has been categorized into lateral flow, flow-through, agglutination assays and solid phase. Each of the above segments are analyzed on the basis of their market size (in terms of USD million) for the period 2011 to 2019. This also includes the forecast of the market segments in terms of CAGR (%) for the period 2013 - 2019, considering 2012 as the base year. Geographically, the rapid medical diagnostic kits market is categorized into four regions namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market revenues (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each of these regions have been included in this report. The market overview section of the report demonstrates the qualitative analysis of the market dynamics of the global rapid medical diagnostic kits market and thus includes information about the drivers, restraints, opportunities, Porter's five forces model and market attractiveness analysis of this industry. Key Topics Covered: Introduction Executive Summary Rapid Medical Diagnostic Kits Market Overview Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Recommendations Competitive Landscape Companies Mentioned - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/md...id_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The US Nutraceuticals Market is Estimated to Reach US$ 75.3 Billion in 2017 says recent Report
M2 - Tue Mar 11, 11:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78hlpr/us_nutraceuticals) has announced the addition of the "US Nutraceuticals Market Forecast to 2017" report to their offering. In the latest research study, US Nutraceuticals Market Forecast to 2017, RNCOS analysts identified and deciphered the market dynamics in important segments to clearly highlight the areas offering promising possibilities for companies to boost their growth. The market, which is estimated to reach US$ 75.3 Billion in 2017, is slated to grow at a CAGR of nearly 6% during 2013-2017. The tremendous growth of the market is driven by factors such as rising consumption of dietary supplements and propelling functional food & beverages market. In the present report, the US nutraceutical market has been broken down into three distinct segments: dietary supplements, functional food and functional beverages, with their current and future outlook to 2017. For market performance analysis, the dietary supplements dominate the market by acquiring a share of around 37%, followed by functional food and functional beverages. In addition, the report also covers the nutraceutical ingredient market along with its sub segments which helped the analysts to clearly identify and highlight the segments that offer the maximum opportunity for growth in the country. The study further delves into the detailed description of the major players in industry, covering description of their business, financials, and their recent developments. This will help the reader to gain a deeper insight into each key market player. Moreover, market drivers and trends have been discussed along with consumer behavior analysis and regulatory framework analysis to provide an understanding of the market dynamics. Companies Mentioned: - Abbott Laboratories - GNC Holdings, Inc. - Mead Johnson Nutrition Company - NBTY Inc. - Nestle USA, Inc. - Perrigo Company - The Hain Celestial Group, Inc. For more information visit http://www.researchandmarkets.com/research/78...aceuticals About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Abbott Laboratories (ABT) Breaks Through Resistance at $40.00
Comtex SmarTrend(R) - Tue Mar 11, 9:31AM CDT
Abbott Laboratories (NYSE:ABT) has opened bullishly above the pivot of $39.71 today and has reached the first level of resistance at $40.00. Should the shares continue to rise, the resistance pivots of $40.19 and $40.67 will be of interest.
Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017
M2 - Tue Mar 11, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nc4zfn/in_vitro) has announced the addition of the "Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017" report to their offering. The in vitro diagnostic market studied in this report has been segmented by technology, product type, application, end user, and geography. The technology market is further segmented into clinical chemistry, immunochemistry, molecular diagnostics, hematology, coagulation, microbiology, and others, of which immunochemistry accounted for the largest share with 25.8% in 2010. By product type, the IVD market has segments like instruments, reagents, data management software/hardware, and services. Based on applications, the in vitro diagnostic market is segmented as diabetes, infectious diseases, oncology, cardiology, nephrology, auto-immune diseases, AIDS, drug testing, and others. Laboratory testing, hospital testing, academic (AMCs and university) testing, point-of-care testing, patient self-testing, and others comprise the end-user segment of the IVD market. The global in vitro diagnostic market was valued at $49.2 billion in 2012 and is expected to reach $69.1 billion by 2017, at a CAGR of 7% from 2012 to 2017. The IVD market is primarily driven by rising incidences of chronic and infectious diseases in emerging economies, a rapidly aging population, the rise in point-of-care testing, and the rising importance of personalized medicine. However, factors such as stringent regulatory frameworks and a shortage of budget and labor are restraining the growth of the market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global In Vitro Diagnostic Market, By Technique 5 Global In Vitro Diagnostic Market, By Product Type 6 Global In Vitro Diagnostic Market, By Application 7 Global In Vitro Diagnostic Market, By End-User 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc - Alere, Inc - Arkray, Inc - Bayer AG - Becton, Dickinson And Company - Bio-Rad Laboratories, Inc - Biomerieux - Danaher Corporation - Diagnostica Stago Sas - Diasorin SPA - Hologic, Inc - Horiba, Ltd - Johnson & Johnson - Novartis International Ag - Qiagen NV - Roche Diagnostics Limited - Siemens Healthcare - Sysmex Corporation - Thermo Fisher Scientific, Inc For more information visit http://www.researchandmarkets.com/research/nc4zfn/in_vitro
2014 Wireless Health and Fitness Devices Global Strategic Business Report - Increasing Obesity Levels Underpins Market Growth
M2 - Tue Mar 11, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/swfb49/wireless_health) has announced the addition of the "Wireless Health and Fitness Devices - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Wireless Health and Fitness Devices in Thousand Units by the following Product Segments: Wireless Sports & Fitness Devices, Wireless Remote Health Monitoring Devices, and Wireless Professional Healthcare Devices. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2011 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK - Wireless Health and Fitness Monitoring Devices Market to Surge - Market Drivers - Wearable Sports and Fitness Devices - Wearable Health Devices - Market Challenges - Wearable Sports and Fitness Devices - Wearable Health Devices 2. TRENDS & ISSUES 3. WIRELESS HEALTH AND FITNESS SOLUTIONS - AN OVERVIEW - Wireless Health and Fitness: An Introduction - Product Segments - Wireless Sports & Fitness Devices - Wireless Remote Health Monitoring Devices - Wireless Professional Healthcare Devices - What is Wireless Health? - Evolution of Wireless Health - Wireless Health Development with M2M Solutions - Value Chain in Mobile Healthcare - Available Wireless Medical Solutions - Wireless Standards for Medical Applications - ZigBee - Bluetooth - Broadband - Wireless Sensor Networks - Applications of Wireless Sensors for Enhanced Healthcare - Chronic Disease Monitoring - Personal Wellness Monitoring - Personal Fitness Monitoring - Benefits of Using Wireless Healthcare Solutions - More Affordable Healthcare - Preventive Healthcare - Better Accessibility to Healthcare - Chronic Disease Management - Key Benefits of Wireless Remote Patient Monitoring Devices - Primary Factors Limiting Success of Remote Patient Monitoring Devices 4. PRODUCT/SERVICE INNOVATIONS/ INTRODUCTIONS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. JAPAN 3. EUROPE 4. ASIA-PACIFIC 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 136 companies including many key and niche players such as: - Abbott Laboratories - Adidas - Alive Technologies - Beuer - BodyMedia - Bosch Healthcare - Entra Health Systems - FitLinxx - Fitbit - Garmin - Ideal Life - Intelesens - Isansys Lifecare - Jawbone - Lumo BodyTech - Medtronic - Nike - Nonin Medical, - Nuvon - Oregon Scientific - Philips Healthcare - Polar Electro - Sensei - Sotera Wireless - Suunto - Toumaz UK - Wahoo Fitness - Withings - Zephyr Technology For more information visit http://www.researchandmarkets.com/research/sw...ess_health About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Investigation Report on China's Telmisartan Market Report 2014 - Forecasts to 2018
M2 - Mon Mar 10, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jqmhqf/investigation) has announced the addition of the "Investigation Report on China Telmisartan Market, 2009-2018" report to their offering. According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack. Angiotensin II receptor antagonist (ABR) is an important product among various antihypertensive drugs. Telmisartan was firstly developed by Boehringer Ingelheim and approved to the U.S. market for the first time in 1999 with the trade name ""Micardis"". It is a once-daily oral medication for the treatment of essential hypertension. In the same year, telmisartan was jointly sold as ""Micardis"" by Boehringer Ingelheim and ""Pritor"" by Glaxo Wellcome in Germany. It was approved to market in December 1999 in Philippines. In 2000, it was approved to market in Australia, Belgium and Britain. Glaxo Wellcome owns the marketing right worldwide except in Japan and the U.S. The company is also developing compound preparation of telmisartan and other hypertension drugs. Abbott Laboratories holds the sales license of this product in the United States. At the end of 2000, Boehringer Ingelheim introduced raw material and preparation of telmisartan into Chinese market. Several telmisartan generic drugs have also been approved to Chinese market in succession since 2004. Statistics shows that incidence of hypertension among Chinese people aged 15 and above is 24%. There are more than 260 million hypertension patients in the country, with at least one hypertension patient among 5 adults. The prevention and cure for hypertension in China is faced with very tough challenges. Less than 40% of hypertension patients are aware of their illness, while only one-fourth of them are under proper management. Among those who are under management, 60% are willing to take medicines, while only 50% of them have their blood pressure under control. According to CRI, more than CNY 40 billion is annually spent on hypertension treatment in China. In 2013, market size of antihypertensive prescription drug in China exceeded CNY 20 billion, increased more than 15% YOY. This has shown great potential of Chinese market. The CAGR of sales value of telmisartan surpassed 65% in Chinese sample hospitals from 2005 to 2010. Its growth rate dropped slightly in 2011, but an annual growth rate of 10% is still maintained. From the perspective of sales revenue, original drug produced by Boehringer Ingelheim has seized most of Chinese telmisartan market while other market share is occupied by generic drugs produced by manufacturers such as Yichang Changjiang Pharmaceutical Co., Ltd. and Beijing Double-Crane Pharmaceutical Co., Ltd. It is estimated that incidence of hypertension in China will continue to rise year by year due to improvement of living standard, changes of eating habit, increasing stress of life and lack of health awareness. As Chinese people's incomes increase, the affordability of antihypertension drugs increases. Estimation shows that market size of telmisartan in China will keep rising in the next few years. For more information visit http://www.researchandmarkets.com/research/jq...estigation
Hill-Rom Elects William G. Dempsey to its Board of Directors
PR Newswire - Mon Mar 10, 7:00AM CDT
Hill-Rom Holdings, Inc. (NYSE: HRC) announced today that William G. Dempsey has been elected to its Board of Directors. He currently serves as a director of Landauer, Inc., Nordion Inc., and Hospira, Inc., and previously held various executive positions with Abbott Laboratories, including Executive Vice President of Global Pharmaceuticals, Senior Vice President of Pharmaceutical Operations, and Senior Vice President of International Operations. He also previously served as Chairman of the International Section of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as Chairman of the Accelerating Access Initiative, a cooperative public-private partnership of UNAIDS, the World Bank, and six research-based pharmaceutical companies.
Abbott Laboratories (ABT) Crosses Pivot Point Support at $39.56
Comtex SmarTrend(R) - Fri Mar 07, 10:16AM CST
Shares of Abbott Laboratories (NYSE:ABT) have bearishly opened below the pivot of $39.90 today and have reached the first support level of $39.56. Investors may be interested in a cross of the next downside pivot targets of $39.40 and $38.90.
RBCC: Analyst Rates n3D a Leading Stakeholder in Explosive Bioprinting Industry
Business Wire - Thu Mar 06, 4:00AM CST
A new research publication lists Rainbow Coral Corp. (OTCBB: RBCC) Nano3D Biosciences (n3D) as a leading stakeholder in an industry forecast to be worth $10 billion by 2030.
Continuous Glucose Monitoring Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 06, 3:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/w77w6d/continuous) has announced the addition of the "Continuous Glucose Monitoring Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid rise in diabetic population across the globe has considerably increased the demand for effective diabetes management systems. Currently, blood glucose meters are widely used for diabetes management; however, the trend is shifting towards minimally invasive (CGMS) or noninvasive glucose monitoring systems as these systems reduce the need for regular finger pricking and also lessen the pain. Continuous glucose monitoring systems are real time glucose sensing and monitoring devices that measure and display glucose levels of a patient at regular intervals. The usage of CGM is substantially increasing over traditional glucose monitoring systems as these systems are user friendly, provide access to real time values and trend, and provide enhanced accuracy. Additionally, it has been observed that continuous glucose monitoring significantly helps in diabetes management especially in type I diabetics, and helps in reducing long-term complications associated with diabetes. Increasing awareness in developed and developing economies, technological advancements and rising number of diabetic patients are some of the key factors that are expected to fuel the growth of this market. According to International Diabetes Federation (IDF) reports, approximately 382 million people globally were diagnosed with diabetes in 2013 and this number is expected to grow to 592 million by 2035. Additionally, as per Juvenile Diabetes Research Foundation (JDRF), the prevalence of type I diabetes rose by 23% in the U.S. between 2001 and 2009 for children under 20 years of age and is identified as the seventh leading cause of death in the country. Hence, rising number of patients suffering from type I diabetes is likely to increase the demand for CGMS. The continuous glucose monitoring market has been segmented on the basis of various CGM systems available in the market including Guardian Real Time CGM System, FreeStyle Navigator, Dexcom Seven Plus, Dexcom G4 Platinum and MiniMed Paradigm Revel/Veo CGM Systems. In 2012, the market for Guardian Real Time CGM system held the largest share globally, followed by Dexcom Seven Plus CGM system. However, during the forecast period 2013 to 2019, growth of the market for Guardian Real Time CGM system is expected to be slowest due to market saturation and development of innovative competitor products. Dexcom G4 Platinum CGM System market is expected to witness the fastest growth during the forecast period. FreeStyle Navigator that witnessed a decline in its market share in 2012 due to product recall from the U.S. market is anticipated to show significant growth during the forecast period due to expected launch of FreeStyle Navigator ll in 2014 in the U.S. market. Key Topics Covered: Preface Executive Summary Market Overview Continuous Glucose Monitoring (CGM) Market, by Device/Brand, 2011 - 2019 (USD Million) Global Continuous Glucose Monitoring Market Revenue, by Geography, 2011 - 2019 (USD Million) Competitive Landscape Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Abbott Laboratories - Bayer AG - Dexcom, Inc. - GlySens Incorporated - Insulet Corporation - Medtronic, Inc. - Nova Biomedical Corporation - Senseonics, Incorporated For more information visit http://www.researchandmarkets.com/research/w77w6d/continuous About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Better Dividend: Abbott Laboratories vs. Medtronic, Inc.
Dan Carroll, The Motley Fool - Motley Fool - Wed Mar 05, 1:30PM CST
In the health-care sector, few stocks boast names as well-known as Medtronic and Abbott Labs . Medtronic's leadership in the medical device sector and Abbott Labs's strength through medical diversity has made it a strong stock for years. Each...
World Glucose Monitoring Device Market to Post 5% CAGR Through 2019, States GBI Research in Its Report Published at MarketPublishers.com
PRWeb - Wed Mar 05, 12:05PM CST
Over the next six years, the value of the world glucose monitoring devices market is anticipated to post a moderate growth at a 5% CAGR. By 2019, it is poised to amount to USD 13.7 billion. Emerging countries such as India and China are considered to have the highest growth potential as they have the largest pools of diabetic population (63 million and 92 million, respectively). The APAC glucose monitoring devices market is predicted to double between 2012 and 2019, and increase from USD 1.5 billion to around USD 3 billion, registering a 10% CAGR through 2019. Meantime, the US and Europe are forecast to maintain their leadership positions in the upcoming years, with shares in the overall market being approximately 34% and 40%, respectively.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Watch for Abbott Laboratories to Potentially Rebound After Falling 1.13% Yesterday
Comtex SmarTrend(R) - Mon Mar 03, 4:36PM CST
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $38.83 to a high of $39.64. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $39.03 on volume of 11.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIOLASE Adds Two New Independent Directors to Its Board
Marketwire - Mon Mar 03, 8:02AM CST
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the Company's proprietary WaterLase(R), and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography, intra oral scanners, and chair-side milling machines and 3-D printers for dentistry, today announced that the Board of Directors (the "Board") has appointed Paul Clark and Jeffrey Nugent to the Board. Dr. Alexander K. Arrow and Dr. Sam Low tendered their resignations from the Board on February 28, 2013. As a result of these appointments and resignations, BIOLASE's Board currently consists of six directors, five of whom are independent directors.
Sucampo Gains On Better-Than-Expected Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:20PM CST
Shares of Sucampo Pharmaceuticals gained 11.9% following the release of fourth quarter results on Feb 26, 2014.
SmarTrend Watching for Potential Rebound in Shares of Abbott Laboratories After 1.08% Loss
Comtex SmarTrend(R) - 1 hr 27 mins ago
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $39.10 to a high of $39.82. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $39.41 on volume of 7.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Pre-Market Health Care Stocks Analysis: Medtronic, Abbott Laboratories, Hologic, and ArthroCare
PR Newswire - Thu Mar 13, 7:00AM CDT
On Wednesday, March 12, 2014, the NASDAQ Composite ended at 4,323.33, up 0.37%, the Dow Jones Industrial Average fell 0.07% to 16,340.08, and the S&P 500 closed at 1,868.20, up 0.03%. The gains were narrow based as four out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 687.90, down 0.01%, while the same has gained 3.36% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Hologic Inc. (NASDAQ: HOLX), and ArthroCare Corporation (NASDAQ: ARTC). Free research on these four companies can be accessed at:
2014 Hormone Replacement Therapy Global Strategic Business Report - IMS Consensus Guidelines Paving Way for More Clarity of HRT
M2 - Thu Mar 13, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/657h9p/hormone) has announced the addition of the "Hormone Replacement Therapy (HRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Hormone Replacement Therapy (HRT) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK 2. INDUSTRY OVERVIEW 3. MARKET TRENDS & ISSUES 4. COMPETITIVE LANDSCAPE 5. THERAPY PROFILE - A REVIEW OF SELECT RECENT STUDIES CONDUCTED - Researchers at Yale University Discover Discontinuation HRT May Lead to Premature Deaths - Bioidenticals versus Synthetic Hormone Replacement Therapy Agents - Studies at University of Sydney Researchers Reveal the Safety of Short-Term Unopposed Estrogens - US Researchers Reveal HRT Risks May be Dependent on Weight and Other Factors - Studies Prove HRT to Lower Risk of Pancreatic Cancer - University of Texas Reveal HRT Linked to Risks of Kidney Stones - Researchers at the Sundsvall Hospital Demonstrate Increased Incidence of Cataract Development in Women Undergoing HRT - Researchers at University of Southern California Demonstrate Estrogen Replacement Therapies Lower Stress Levels in Older Women - Studies at Uppsala University Hospital Demonstrate HRT is Associated with Improved Muscle Functioning in Postmenopausal women - Finnish Study Reveals HRT Usage Assist in the Treatment of Hot Flashes in Post Menopausal Women - Researchers at Johns Hopkins University Demonstrate Women Undergoing Hormone Therapy Less Prone to Alzheimer's Disease - French Study Reveals Hormone Replacement Pills May Affect Gall Bladder - Danish Studies Proves HRT Lowers Risk of Heart Attack and Heart Failure 6. PRODUCT OVERVIEW 7. PRODUCT INTRODUCTIONS/APPROVALS - Pfizer Receives FDA Approval for DUAVEE for Treatment of Vasomotor Symptoms - Noven Pharmaceuticals Launches Brisdelle Capsules - Lawley Pharmaceuticals Launches Profeme progesterone Bioidentical Hormone Replacement Cream - Bayer Receives FDA Approval for Low-Dose ANGELIQ? Tablets - Noven Pharmaceuticals Receives USFDA Approval for Minivelle - Mylan Pharmaceuticals Introduces Letrozole Tablets - Novo Nordisk Unveils Vagifem? 10?g - Amgen Obtains FDA Approval for Prolia in Treating Postmenopausal Women at Greater Risk of Osteoporosis 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. EUROPE 4. ASIA-PACIFIC 5. LATIN AMERICA 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 40 companies including many key and niche players such as: - Abbott Laboratories - AbbVie - Actavis - Bayer Pharma - Bayer Pharma's Hormone Replacement Therapy Product Pipeline - Hisamitsu Pharmaceutical - Noven Pharmaceuticals - Merck Sharp & Dohme - Novartis - Novo Nordisk - Orion - Pfizer - Rottapharm Madaus - Teva Pharmaceutical Industries - TherapeuticsMD - Upsher-Smith Laboratories For more information visit http://www.researchandmarkets.com/research/657h9p/hormone About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Chinese Adalimumab Market Report - Forecasts to 2018
M2 - Wed Mar 12, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/936hbj/investigation) has announced the addition of the "Chinese Adalimumab Market Report - Forecasts to 2018" report to their offering. Adalimumab is a TNF (tumor necrosis factor) inhibiting anti-inflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA. Duo to large market size, challenging R&D and high profit of the monoclonal antibody drug market, the collaboration between Huahai Pharmaceutical and Oncobiologics is praised by the industry as the ""Second Transformation"" supported by the international biopharmaceutical giant's strong R&D strength. The approval for adalimumab to launch phase I clinical trial means a significant progress of the collaboration. However, follow-up R&D of the monoclonal antibody product requires a large amount of time before the product appears on the market. It is estimated that Abbott will continue to occupy the global market of adalimumab in the next few years. However, the situation will change gradually after 2017. Key Topics Covered: 1 Relevant Concepts of Adalimumab 2 Market Overview of Adalimumab in China, 2010-2013 3 Investigation on Sales Value of Adalimumab in China, 2010-2013 4 Investigation on Market Share of Major Adalimumab Manufacturers in China, 2010-2013 5 Investigation on Market Size of Adalimumab by Dosage Form in China, 2010-2013 6 Reference Price of Adalimumab in China Adalimumab Hospital Market, 2013 7 Analysis on Major Adalimumab Manufacturers in China, 2010-2013 8 Prospect of China Adalimumab Market, 2014-2018 Companies Mentioned - AbbVie - BASF Bioresearch Corporation - BASF Pharma - Huahai Pharmaceutical For more information visit http://www.researchandmarkets.com/research/93...estigation
Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Wed Mar 12, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mdgmns/rapid_medical) has announced the addition of the "Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid medical diagnostic kits market is experiencing impressive growth globally because of the continuous increase in demand for preventive management of infectious diseases. Since its introduction, rapid medical diagnostic kits are becoming a vital part of the medical diagnostics industry and the scope of this market has been perpetually increasing in terms of detectable diseases and adoption by end users. This report studies the global market for rapid diagnostic kits through three major perspectives namely, application areas, technologies and geography. The application segment of this market has been further segmented into three sub-divisions namely clinical testing, home-use and veterinary diagnostics. In addition, the technology segment of rapid medical diagnostic kits market has been categorized into lateral flow, flow-through, agglutination assays and solid phase. Each of the above segments are analyzed on the basis of their market size (in terms of USD million) for the period 2011 to 2019. This also includes the forecast of the market segments in terms of CAGR (%) for the period 2013 - 2019, considering 2012 as the base year. Geographically, the rapid medical diagnostic kits market is categorized into four regions namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market revenues (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each of these regions have been included in this report. The market overview section of the report demonstrates the qualitative analysis of the market dynamics of the global rapid medical diagnostic kits market and thus includes information about the drivers, restraints, opportunities, Porter's five forces model and market attractiveness analysis of this industry. Key Topics Covered: Introduction Executive Summary Rapid Medical Diagnostic Kits Market Overview Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Recommendations Competitive Landscape Companies Mentioned - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/md...id_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The US Nutraceuticals Market is Estimated to Reach US$ 75.3 Billion in 2017 says recent Report
M2 - Tue Mar 11, 11:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78hlpr/us_nutraceuticals) has announced the addition of the "US Nutraceuticals Market Forecast to 2017" report to their offering. In the latest research study, US Nutraceuticals Market Forecast to 2017, RNCOS analysts identified and deciphered the market dynamics in important segments to clearly highlight the areas offering promising possibilities for companies to boost their growth. The market, which is estimated to reach US$ 75.3 Billion in 2017, is slated to grow at a CAGR of nearly 6% during 2013-2017. The tremendous growth of the market is driven by factors such as rising consumption of dietary supplements and propelling functional food & beverages market. In the present report, the US nutraceutical market has been broken down into three distinct segments: dietary supplements, functional food and functional beverages, with their current and future outlook to 2017. For market performance analysis, the dietary supplements dominate the market by acquiring a share of around 37%, followed by functional food and functional beverages. In addition, the report also covers the nutraceutical ingredient market along with its sub segments which helped the analysts to clearly identify and highlight the segments that offer the maximum opportunity for growth in the country. The study further delves into the detailed description of the major players in industry, covering description of their business, financials, and their recent developments. This will help the reader to gain a deeper insight into each key market player. Moreover, market drivers and trends have been discussed along with consumer behavior analysis and regulatory framework analysis to provide an understanding of the market dynamics. Companies Mentioned: - Abbott Laboratories - GNC Holdings, Inc. - Mead Johnson Nutrition Company - NBTY Inc. - Nestle USA, Inc. - Perrigo Company - The Hain Celestial Group, Inc. For more information visit http://www.researchandmarkets.com/research/78...aceuticals About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Abbott Laboratories (ABT) Breaks Through Resistance at $40.00
Comtex SmarTrend(R) - Tue Mar 11, 9:31AM CDT
Abbott Laboratories (NYSE:ABT) has opened bullishly above the pivot of $39.71 today and has reached the first level of resistance at $40.00. Should the shares continue to rise, the resistance pivots of $40.19 and $40.67 will be of interest.
Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017
M2 - Tue Mar 11, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nc4zfn/in_vitro) has announced the addition of the "Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017" report to their offering. The in vitro diagnostic market studied in this report has been segmented by technology, product type, application, end user, and geography. The technology market is further segmented into clinical chemistry, immunochemistry, molecular diagnostics, hematology, coagulation, microbiology, and others, of which immunochemistry accounted for the largest share with 25.8% in 2010. By product type, the IVD market has segments like instruments, reagents, data management software/hardware, and services. Based on applications, the in vitro diagnostic market is segmented as diabetes, infectious diseases, oncology, cardiology, nephrology, auto-immune diseases, AIDS, drug testing, and others. Laboratory testing, hospital testing, academic (AMCs and university) testing, point-of-care testing, patient self-testing, and others comprise the end-user segment of the IVD market. The global in vitro diagnostic market was valued at $49.2 billion in 2012 and is expected to reach $69.1 billion by 2017, at a CAGR of 7% from 2012 to 2017. The IVD market is primarily driven by rising incidences of chronic and infectious diseases in emerging economies, a rapidly aging population, the rise in point-of-care testing, and the rising importance of personalized medicine. However, factors such as stringent regulatory frameworks and a shortage of budget and labor are restraining the growth of the market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global In Vitro Diagnostic Market, By Technique 5 Global In Vitro Diagnostic Market, By Product Type 6 Global In Vitro Diagnostic Market, By Application 7 Global In Vitro Diagnostic Market, By End-User 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc - Alere, Inc - Arkray, Inc - Bayer AG - Becton, Dickinson And Company - Bio-Rad Laboratories, Inc - Biomerieux - Danaher Corporation - Diagnostica Stago Sas - Diasorin SPA - Hologic, Inc - Horiba, Ltd - Johnson & Johnson - Novartis International Ag - Qiagen NV - Roche Diagnostics Limited - Siemens Healthcare - Sysmex Corporation - Thermo Fisher Scientific, Inc For more information visit http://www.researchandmarkets.com/research/nc4zfn/in_vitro
2014 Wireless Health and Fitness Devices Global Strategic Business Report - Increasing Obesity Levels Underpins Market Growth
M2 - Tue Mar 11, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/swfb49/wireless_health) has announced the addition of the "Wireless Health and Fitness Devices - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Wireless Health and Fitness Devices in Thousand Units by the following Product Segments: Wireless Sports & Fitness Devices, Wireless Remote Health Monitoring Devices, and Wireless Professional Healthcare Devices. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2011 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. OUTLOOK - Wireless Health and Fitness Monitoring Devices Market to Surge - Market Drivers - Wearable Sports and Fitness Devices - Wearable Health Devices - Market Challenges - Wearable Sports and Fitness Devices - Wearable Health Devices 2. TRENDS & ISSUES 3. WIRELESS HEALTH AND FITNESS SOLUTIONS - AN OVERVIEW - Wireless Health and Fitness: An Introduction - Product Segments - Wireless Sports & Fitness Devices - Wireless Remote Health Monitoring Devices - Wireless Professional Healthcare Devices - What is Wireless Health? - Evolution of Wireless Health - Wireless Health Development with M2M Solutions - Value Chain in Mobile Healthcare - Available Wireless Medical Solutions - Wireless Standards for Medical Applications - ZigBee - Bluetooth - Broadband - Wireless Sensor Networks - Applications of Wireless Sensors for Enhanced Healthcare - Chronic Disease Monitoring - Personal Wellness Monitoring - Personal Fitness Monitoring - Benefits of Using Wireless Healthcare Solutions - More Affordable Healthcare - Preventive Healthcare - Better Accessibility to Healthcare - Chronic Disease Management - Key Benefits of Wireless Remote Patient Monitoring Devices - Primary Factors Limiting Success of Remote Patient Monitoring Devices 4. PRODUCT/SERVICE INNOVATIONS/ INTRODUCTIONS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. JAPAN 3. EUROPE 4. ASIA-PACIFIC 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 136 companies including many key and niche players such as: - Abbott Laboratories - Adidas - Alive Technologies - Beuer - BodyMedia - Bosch Healthcare - Entra Health Systems - FitLinxx - Fitbit - Garmin - Ideal Life - Intelesens - Isansys Lifecare - Jawbone - Lumo BodyTech - Medtronic - Nike - Nonin Medical, - Nuvon - Oregon Scientific - Philips Healthcare - Polar Electro - Sensei - Sotera Wireless - Suunto - Toumaz UK - Wahoo Fitness - Withings - Zephyr Technology For more information visit http://www.researchandmarkets.com/research/sw...ess_health About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Investigation Report on China's Telmisartan Market Report 2014 - Forecasts to 2018
M2 - Mon Mar 10, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jqmhqf/investigation) has announced the addition of the "Investigation Report on China Telmisartan Market, 2009-2018" report to their offering. According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack. Angiotensin II receptor antagonist (ABR) is an important product among various antihypertensive drugs. Telmisartan was firstly developed by Boehringer Ingelheim and approved to the U.S. market for the first time in 1999 with the trade name ""Micardis"". It is a once-daily oral medication for the treatment of essential hypertension. In the same year, telmisartan was jointly sold as ""Micardis"" by Boehringer Ingelheim and ""Pritor"" by Glaxo Wellcome in Germany. It was approved to market in December 1999 in Philippines. In 2000, it was approved to market in Australia, Belgium and Britain. Glaxo Wellcome owns the marketing right worldwide except in Japan and the U.S. The company is also developing compound preparation of telmisartan and other hypertension drugs. Abbott Laboratories holds the sales license of this product in the United States. At the end of 2000, Boehringer Ingelheim introduced raw material and preparation of telmisartan into Chinese market. Several telmisartan generic drugs have also been approved to Chinese market in succession since 2004. Statistics shows that incidence of hypertension among Chinese people aged 15 and above is 24%. There are more than 260 million hypertension patients in the country, with at least one hypertension patient among 5 adults. The prevention and cure for hypertension in China is faced with very tough challenges. Less than 40% of hypertension patients are aware of their illness, while only one-fourth of them are under proper management. Among those who are under management, 60% are willing to take medicines, while only 50% of them have their blood pressure under control. According to CRI, more than CNY 40 billion is annually spent on hypertension treatment in China. In 2013, market size of antihypertensive prescription drug in China exceeded CNY 20 billion, increased more than 15% YOY. This has shown great potential of Chinese market. The CAGR of sales value of telmisartan surpassed 65% in Chinese sample hospitals from 2005 to 2010. Its growth rate dropped slightly in 2011, but an annual growth rate of 10% is still maintained. From the perspective of sales revenue, original drug produced by Boehringer Ingelheim has seized most of Chinese telmisartan market while other market share is occupied by generic drugs produced by manufacturers such as Yichang Changjiang Pharmaceutical Co., Ltd. and Beijing Double-Crane Pharmaceutical Co., Ltd. It is estimated that incidence of hypertension in China will continue to rise year by year due to improvement of living standard, changes of eating habit, increasing stress of life and lack of health awareness. As Chinese people's incomes increase, the affordability of antihypertension drugs increases. Estimation shows that market size of telmisartan in China will keep rising in the next few years. For more information visit http://www.researchandmarkets.com/research/jq...estigation
Hill-Rom Elects William G. Dempsey to its Board of Directors
PR Newswire - Mon Mar 10, 7:00AM CDT
Hill-Rom Holdings, Inc. (NYSE: HRC) announced today that William G. Dempsey has been elected to its Board of Directors. He currently serves as a director of Landauer, Inc., Nordion Inc., and Hospira, Inc., and previously held various executive positions with Abbott Laboratories, including Executive Vice President of Global Pharmaceuticals, Senior Vice President of Pharmaceutical Operations, and Senior Vice President of International Operations. He also previously served as Chairman of the International Section of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as Chairman of the Accelerating Access Initiative, a cooperative public-private partnership of UNAIDS, the World Bank, and six research-based pharmaceutical companies.
Abbott Laboratories (ABT) Crosses Pivot Point Support at $39.56
Comtex SmarTrend(R) - Fri Mar 07, 10:16AM CST
Shares of Abbott Laboratories (NYSE:ABT) have bearishly opened below the pivot of $39.90 today and have reached the first support level of $39.56. Investors may be interested in a cross of the next downside pivot targets of $39.40 and $38.90.
RBCC: Analyst Rates n3D a Leading Stakeholder in Explosive Bioprinting Industry
Business Wire - Thu Mar 06, 4:00AM CST
A new research publication lists Rainbow Coral Corp. (OTCBB: RBCC) Nano3D Biosciences (n3D) as a leading stakeholder in an industry forecast to be worth $10 billion by 2030.
Continuous Glucose Monitoring Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 06, 3:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/w77w6d/continuous) has announced the addition of the "Continuous Glucose Monitoring Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid rise in diabetic population across the globe has considerably increased the demand for effective diabetes management systems. Currently, blood glucose meters are widely used for diabetes management; however, the trend is shifting towards minimally invasive (CGMS) or noninvasive glucose monitoring systems as these systems reduce the need for regular finger pricking and also lessen the pain. Continuous glucose monitoring systems are real time glucose sensing and monitoring devices that measure and display glucose levels of a patient at regular intervals. The usage of CGM is substantially increasing over traditional glucose monitoring systems as these systems are user friendly, provide access to real time values and trend, and provide enhanced accuracy. Additionally, it has been observed that continuous glucose monitoring significantly helps in diabetes management especially in type I diabetics, and helps in reducing long-term complications associated with diabetes. Increasing awareness in developed and developing economies, technological advancements and rising number of diabetic patients are some of the key factors that are expected to fuel the growth of this market. According to International Diabetes Federation (IDF) reports, approximately 382 million people globally were diagnosed with diabetes in 2013 and this number is expected to grow to 592 million by 2035. Additionally, as per Juvenile Diabetes Research Foundation (JDRF), the prevalence of type I diabetes rose by 23% in the U.S. between 2001 and 2009 for children under 20 years of age and is identified as the seventh leading cause of death in the country. Hence, rising number of patients suffering from type I diabetes is likely to increase the demand for CGMS. The continuous glucose monitoring market has been segmented on the basis of various CGM systems available in the market including Guardian Real Time CGM System, FreeStyle Navigator, Dexcom Seven Plus, Dexcom G4 Platinum and MiniMed Paradigm Revel/Veo CGM Systems. In 2012, the market for Guardian Real Time CGM system held the largest share globally, followed by Dexcom Seven Plus CGM system. However, during the forecast period 2013 to 2019, growth of the market for Guardian Real Time CGM system is expected to be slowest due to market saturation and development of innovative competitor products. Dexcom G4 Platinum CGM System market is expected to witness the fastest growth during the forecast period. FreeStyle Navigator that witnessed a decline in its market share in 2012 due to product recall from the U.S. market is anticipated to show significant growth during the forecast period due to expected launch of FreeStyle Navigator ll in 2014 in the U.S. market. Key Topics Covered: Preface Executive Summary Market Overview Continuous Glucose Monitoring (CGM) Market, by Device/Brand, 2011 - 2019 (USD Million) Global Continuous Glucose Monitoring Market Revenue, by Geography, 2011 - 2019 (USD Million) Competitive Landscape Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Abbott Laboratories - Bayer AG - Dexcom, Inc. - GlySens Incorporated - Insulet Corporation - Medtronic, Inc. - Nova Biomedical Corporation - Senseonics, Incorporated For more information visit http://www.researchandmarkets.com/research/w77w6d/continuous About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Better Dividend: Abbott Laboratories vs. Medtronic, Inc.
Dan Carroll, The Motley Fool - Motley Fool - Wed Mar 05, 1:30PM CST
In the health-care sector, few stocks boast names as well-known as Medtronic and Abbott Labs . Medtronic's leadership in the medical device sector and Abbott Labs's strength through medical diversity has made it a strong stock for years. Each...
World Glucose Monitoring Device Market to Post 5% CAGR Through 2019, States GBI Research in Its Report Published at MarketPublishers.com
PRWeb - Wed Mar 05, 12:05PM CST
Over the next six years, the value of the world glucose monitoring devices market is anticipated to post a moderate growth at a 5% CAGR. By 2019, it is poised to amount to USD 13.7 billion. Emerging countries such as India and China are considered to have the highest growth potential as they have the largest pools of diabetic population (63 million and 92 million, respectively). The APAC glucose monitoring devices market is predicted to double between 2012 and 2019, and increase from USD 1.5 billion to around USD 3 billion, registering a 10% CAGR through 2019. Meantime, the US and Europe are forecast to maintain their leadership positions in the upcoming years, with shares in the overall market being approximately 34% and 40%, respectively.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Watch for Abbott Laboratories to Potentially Rebound After Falling 1.13% Yesterday
Comtex SmarTrend(R) - Mon Mar 03, 4:36PM CST
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $38.83 to a high of $39.64. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $39.03 on volume of 11.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIOLASE Adds Two New Independent Directors to Its Board
Marketwire - Mon Mar 03, 8:02AM CST
BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the Company's proprietary WaterLase(R), and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography, intra oral scanners, and chair-side milling machines and 3-D printers for dentistry, today announced that the Board of Directors (the "Board") has appointed Paul Clark and Jeffrey Nugent to the Board. Dr. Alexander K. Arrow and Dr. Sam Low tendered their resignations from the Board on February 28, 2013. As a result of these appointments and resignations, BIOLASE's Board currently consists of six directors, five of whom are independent directors.
Sucampo Gains On Better-Than-Expected Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:20PM CST
Shares of Sucampo Pharmaceuticals gained 11.9% following the release of fourth quarter results on Feb 26, 2014.
(0)
(0)Abbott Laboratories (ABT) Stock Research Links
Scroll down for more posts ▼